Shankar MBA - Ocugen CEO CoFounder

OCGN Stock  USD 0.92  0.01  1.10%   

CEO

Shankar MBA is CEO CoFounder of Ocugen Inc
Age 60
Address 11 Great Valley Parkway, Malvern, PA, United States, 19355
Phone484 328 4701
Webhttps://www.ocugen.com

Ocugen Management Efficiency

The company has return on total asset (ROA) of (0.4798) % which means that it has lost $0.4798 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0329) %, meaning that it created substantial loss on money invested by shareholders. Ocugen's management efficiency ratios could be used to measure how well Ocugen manages its routine affairs as well as how well it operates its assets and liabilities. As of the 26th of November 2024, Return On Tangible Assets is likely to drop to -1.03. In addition to that, Return On Capital Employed is likely to drop to -1.45. At this time, Ocugen's Non Current Assets Total are very stable compared to the past year. As of the 26th of November 2024, Non Currrent Assets Other is likely to grow to about 4.5 M, while Total Assets are likely to drop about 48.2 M.
Ocugen Inc currently holds 6.94 M in liabilities with Debt to Equity (D/E) ratio of 0.07, which may suggest the company is not taking enough advantage from borrowing. Ocugen Inc has a current ratio of 7.07, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Ocugen's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Found 4 records

CEO Age

Stanley ErckNovavax
76
Steven LoVaxart Inc
57
John MBANovavax
57
Elizabeth MBAOcean Biomedical
67
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing and Bharat Biotech for the commercialization of COVAXIN in the United States market. Ocugen operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 56 people. Ocugen Inc (OCGN) is traded on NASDAQ Exchange in USA. It is located in 11 Great Valley Parkway, Malvern, PA, United States, 19355 and employs 65 people. Ocugen is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Ocugen Inc Leadership Team

Elected by the shareholders, the Ocugen's board of directors comprises two types of representatives: Ocugen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ocugen. The board's role is to monitor Ocugen's management team and ensure that shareholders' interests are well served. Ocugen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ocugen's outside directors are responsible for providing unbiased perspectives on the board's policies.
CPA CPA, Sr Officer
CMA CPA, Chief Officer
Michael Shine, VP Commercial
Michael MBA, Senior Commercial
Shankar MBA, CEO CoFounder
Durgaprasad Annavajjula, Head VP
Arun Upadhyay, Chief Development
Uday Kompella, Cofounder Director
CMI MD, Chief Officer
John JD, General Counsel
Jyothy MS, Head Quality
Tiffany MBA, Head Communications
Zara Gaudioso, Head AVP
MBA MBA, Chairman CoFounder
Vijay Tammara, VP Quality
FACP MD, Chief Officer
Kristen Craft, Head Culture

Ocugen Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ocugen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
When determining whether Ocugen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Ocugen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ocugen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Ocugen Inc Stock:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ocugen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ocugen. If investors know Ocugen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ocugen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.19)
Revenue Per Share
0.018
Quarterly Revenue Growth
1.353
Return On Assets
(0.48)
Return On Equity
(1.03)
The market value of Ocugen Inc is measured differently than its book value, which is the value of Ocugen that is recorded on the company's balance sheet. Investors also form their own opinion of Ocugen's value that differs from its market value or its book value, called intrinsic value, which is Ocugen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ocugen's market value can be influenced by many factors that don't directly affect Ocugen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ocugen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ocugen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ocugen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.